CDK18 Antibody

What is CDK18 and what cellular functions should researchers consider when selecting antibodies?

CDK18 (Cyclin-Dependent Kinase 18, also known as PCTAIRE3 or PCTK3) is a 54.4 kDa serine/threonine protein kinase with reported roles in signal transduction cascades in terminally differentiated cells . More significantly, recent research has revealed CDK18's critical function in replication stress signaling and genome stability .

When selecting antibodies, researchers should consider:

• CDK18 has up to 2 different reported isoforms with the canonical protein length of 474 amino acids

• It is widely expressed across many tissue types

• It participates in ATR activation by regulating ATR-Rad9/ATR-ETAA1 interactions

• Its involvement in homologous recombination (HR) repair mechanisms

Methodological approach: Select antibodies targeting conserved regions if studying general CDK18 functions, or isoform-specific regions if differentiating between variants. Consider antibodies validated for your specific application (WB, IHC, ICC) and sample type.

How should researchers validate CDK18 antibody specificity for experimental applications?

Validation should follow a multi-step approach:

• Positive and negative controls: Use cell lines with known CDK18 expression levels. FFPE sections of cells transfected with CDK18 siRNA versus non-targeting control siRNA provide excellent validation controls for IHC applications .

• Multiple validation techniques: Cross-validate using:

  • Western blot to confirm correct molecular weight (54 kDa)

  • siRNA knockdown to demonstrate specificity

  • Orthogonal RNAseq validation

  • Protein array testing against human recombinant protein fragments

• Cross-reactivity assessment: Some CDK18 antibodies are validated against 364 human recombinant protein fragments to ensure specificity .

• Application-specific validation: For IHC, test antibodies on tissue microarrays comprising various cancer lineages, stages, grades, normal tissue, and cancer-adjacent controls .

What are the optimal working dilutions and conditions for different CDK18 antibody applications?

Based on research protocols across multiple sources:

Methodological note: Always perform titration experiments to determine optimal conditions for your specific experimental system. The wide range of reported dilutions highlights the importance of optimization.

How should researchers store and handle CDK18 antibodies to maintain reactivity and specificity?

For optimal antibody performance:

• Storage temperature:

  • Long-term: Store at -20°C (most vendors recommend this for up to 12-24 months)

  • Working stocks: 4°C for frequent use (up to 6 months)

• Aliquoting strategy:

  • Divide into single-use aliquots before freezing to avoid repeated freeze-thaw cycles

  • Multiple sources emphasize avoiding freeze-thaw cycles

• Buffer composition:

  • Most CDK18 antibodies are supplied in PBS containing 50% glycerol and 0.02% sodium azide

  • This formulation helps maintain stability during freeze-thaw

• Quality control tracking:

  • Perform parallel testing with previously validated lots

  • Document lot-to-lot variations

Methodological recommendation: Create a validation schedule where the same antibody lot is tested every 3-6 months to track potential degradation over time.

How does CDK18 expression correlate with breast cancer subtypes and how can researchers investigate this relationship?

Research has revealed significant correlations between CDK18 expression and breast cancer characteristics:

• Triple-negative and basal-like correlation:

  • High CDK18 protein expression is associated with triple-negative phenotype (p = 0.021) and basal-like phenotype (p = 0.027)

  • Conversely, low CDK18 expression correlates with HER2 overexpression (p < 0.001)

• Survival outcomes:

  • High CDK18 expression correlates with improved patient survival

  • This is particularly significant in ER-negative breast cancers (n = 594, Log Rank 6.724, p = 0.01)

  • Also significant in patients treated with chemotherapy (n = 270, Log Rank 4.575, p = 0.03)

• DNA repair marker associations:

  • High cytoplasmic CDK18 associates with high ATR (p = 0.005), APE1 (p < 0.001), Polβ (p < 0.001), and DNA-PKcs (p < 0.001)

  • Also links to cell cycle regulation markers including phosphorylated CHK1 (p = 0.001) and others

Methodological approach for researchers:

• Use multiparameter IHC to correlate CDK18 with other markers

• Employ tissue microarrays for higher throughput analysis

• Consider subcellular localization (cytoplasmic vs. nuclear) in scoring systems

• Use automated quantification systems to reduce subjective interpretation

What molecular mechanisms explain CDK18's role in chemosensitivity, and how can researchers investigate this experimentally?

The correlation between CDK18 expression and chemosensitivity is mechanistically linked to its function in replication stress responses:

• Replication stress signaling:

  • CDK18 facilitates ATR activation by regulating ATR-Rad9/ATR-ETAA1 interactions

  • This promotes homologous recombination (HR) and impacts PARP inhibitor resistance

• Experimental models of CDK18 manipulation:

  • dCRISPR approaches have been used to express high levels of endogenous CDK18

  • These models demonstrated increased sensitivity to replication stress-inducing chemotherapeutic agents

  • This sensitivity is linked to defective replication stress signaling at the molecular level

• Combined targeted therapy:

  • CDK18 knockdown or ATR inhibition in glioblastoma stem-like cells (GSCs) suppressed HR and conferred PARP inhibitor sensitivity

  • ATR inhibitors synergized with PARP inhibitors in preclinical models

Methodological approaches for researchers:

• Use genetic manipulation techniques (siRNA, CRISPR/Cas9) to modulate CDK18 levels

• Employ CDK18 antibodies to verify knockdown/overexpression efficiency

• Conduct cell viability/cytotoxicity assays with various chemotherapeutic agents

• Analyze DNA damage markers (γH2AX, 53BP1) after treatment

• Perform DNA fiber assays to directly measure replication stress

How can researchers investigate CDK18 interactions with ATR and other replication stress components using antibody-based approaches?

CDK18's interaction with ATR and its role in replication stress response can be studied through several antibody-based techniques:

• Co-immunoprecipitation (Co-IP):

  • Use validated CDK18 antibodies (such as Santa Cruz sc-176) for IP

  • Probe for ATR, ATRIP, RAD9, RAD17, RPA2, and other replication stress components

  • Recent studies have shown CDK18 facilitates ATR activation by regulating ATR-Rad9/ATR-ETAA1 interactions

• Proximity ligation assay (PLA):

  • Allows visualization of protein-protein interactions in situ

  • Requires specific primary antibodies against CDK18 and potential interacting partners

  • Particularly useful for detecting transient interactions during replication stress

• Chromatin immunoprecipitation (ChIP):

  • Can detect CDK18 recruitment to sites of DNA damage

  • Combine with sequencing (ChIP-seq) to map genome-wide interactions

• Sequential immunoprecipitation:

  • First IP with CDK18 antibody followed by IP with interacting protein antibody

  • Helps identify specific complexes rather than binary interactions

Methodological considerations:

• Use appropriate negative controls (IgG, irrelevant antibodies)

• Consider cell synchronization to enrich for specific cell cycle phases

• Apply replication stress inducers (hydroxyurea, aphidicolin) to stimulate interactions

• Validate findings with reciprocal IP experiments

What phosphorylation events regulate CDK18 activity and how can researchers detect these modifications?

While the search results don't provide comprehensive information about CDK18 phosphorylation events specifically, researchers can apply these methodological approaches:

• Phospho-specific antibodies:

  • Anti-pCDK substrate (phosphor-[K/H]pSP) antibodies can detect CDK18 substrates

  • Mass spectrometry data suggests potential phosphorylation sites that could be targeted

• Phosphatase treatment controls:

  • Compare antibody detection before/after λ-phosphatase treatment

  • Helps confirm that observed shifts are due to phosphorylation

• In vitro kinase assays:

  • Using recombinant CDK18 and potential kinase partners

  • Detect phosphorylation using radiolabeled ATP or phospho-specific antibodies

• 2D gel electrophoresis:

  • Separate phosphorylated from non-phosphorylated forms

  • Western blot with CDK18 antibodies to identify phospho-isoforms

For research design, consider:

• Cell cycle synchronization (CDK activity changes throughout the cell cycle)

• Treatment with DNA damaging agents (may alter CDK18 phosphorylation)

• Use of specific kinase or phosphatase inhibitors to map regulatory pathways

What are common issues with CDK18 antibody applications and how can researchers troubleshoot them?

Based on the technical information available in the search results:

• Non-specific bands in Western blot:

  • Optimize antibody dilution (try recommended ranges: 1:500-2000 or 1:50-400)

  • Increase blocking reagent concentration (5% milk in PBS is commonly used)

  • Consider using different CDK18 antibodies targeting different epitopes

  • Use lysates from CDK18 knockdown cells as negative controls

• Weak signal in IHC/ICC:

  • Optimize antigen retrieval methods

  • Test different antibody concentrations (1:10-100 for paraffin sections)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure tissue fixation conditions are appropriate for epitope preservation

• Background in immunofluorescence:

  • Optimize antibody concentration (0.25-2 μg/mL recommended)

  • Include additional blocking steps

  • Use specific secondary antibodies with minimal cross-reactivity

  • Include appropriate controls (no primary antibody, isotype controls)

• Lot-to-lot variability:

  • Always validate new antibody lots against previously validated lots

  • Keep detailed records of performance with each lot

  • Consider stocking larger amounts of validated lots for long-term studies

Methodological approach for validation:

• Always include proper controls (positive, negative, isotype)

• Test multiple commercially available antibodies where possible

• Consider epitope location when selecting antibodies

How can researchers optimize CDK18 antibody-based detection in challenging sample types?

For researchers working with difficult sample types:

• FFPE tissue samples:

  • Extended antigen retrieval methods may be necessary

  • Trypsin digestion or pressure cooking in citrate buffer can improve epitope accessibility

  • Antibody validation on FFPE control cell pellets is recommended

  • Test different antibody dilutions (1:50-1:200 range for IHC)

• Archived or degraded samples:

  • Target antibodies recognizing more stable epitopes

  • Consider antibodies against linear rather than conformational epitopes

  • Increase antibody concentration and incubation time

  • Use signal amplification systems (tyramide signal amplification)

• Low expression samples:

  • Use more sensitive detection methods (SuperSignal West Femto for WB)

  • Consider immunoprecipitation before Western blot

  • For IHC/IF, use high-sensitivity polymer detection systems

• Tissues with high autofluorescence:

  • Use Sudan Black B to reduce autofluorescence

  • Consider non-fluorescent detection methods

  • Use spectral unmixing on confocal systems

Methodological recommendations:

• Always include positive control samples with known high CDK18 expression

• Process experimental and control samples identically

• Consider multiplexed approaches to maximize data from limited samples

• Document all optimization steps for reproducibility

How can CDK18 antibodies be utilized in combination with ATR inhibitors for potential therapeutic strategies?

Based on research findings, CDK18 and ATR inhibition present important opportunities:

• Mechanism-based rationale:

  • CDK18 facilitates ATR activation by regulating ATR-Rad9/ATR-ETAA1 interactions

  • CDK18 knockdown or ATR inhibition in GSCs suppressed HR and conferred PARP inhibitor sensitivity

  • ATR inhibitors synergized with PARP inhibitors or sensitized GSCs

• Experimental approaches:

  • Use CDK18 antibodies to monitor expression levels before/after treatment

  • Study phosphorylation status of ATR substrates (CHK1 pS317) using phospho-specific antibodies

  • Analyze DNA damage markers and replication stress indicators (RPA2 pT21, RPA2 pS4/8)

• Combined therapy evaluation:

  • ATR inhibitor VE822 combined with PARP inhibitor extended survival of mice bearing GSC-derived orthotopic tumors

  • This effect occurred irrespective of PARP inhibitor sensitivity

Methodological approach for researchers:

• Use validated CDK18 antibodies to stratify tumor samples by expression level

• Combine with phospho-specific antibodies against ATR substrates

• Design in vitro and in vivo studies testing combined ATR/PARP inhibition

• Consider genetic approaches (CRISPR/siRNA) to validate antibody findings

How does CDK18 expression in different cancer types correlate with tumor characteristics and treatment responses?

While the search results primarily focus on breast cancer, researchers can apply similar methodologies to study CDK18 in other cancer types:

• Expression patterns across cancer types:

  • In breast cancer, high CDK18 protein expression associates with triple-negative and basal-like phenotypes

  • In glioblastoma, a minority of patients in The Cancer Genome Atlas GBM dataset had MYC, MYCN, or CDK18 amplifications or altered mRNA levels

  • MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARP inhibitor via Myc-mediated transcriptional repression of CDK18

• Correlation with therapeutic response:

  • In breast cancer, high CDK18 expression correlates with improved survival in patients treated with chemotherapy (n = 270, Log Rank 4.575, p = 0.03)

  • In glioblastoma, CDK18 knockdown or ATR inhibition in GSCs suppressed HR and conferred PARP inhibitor sensitivity

Methodological approaches for researchers:

• Develop tissue microarrays for specific cancer types of interest

• Quantify CDK18 expression using validated antibodies and scoring systems

• Correlate with clinical parameters and treatment outcomes

• Combine with other biomarkers to develop predictive signatures

• Consider subcellular localization in scoring systems